miR-122, the downregulation of which has been identified both in patients with HCC and HCC-derived cell lines [13–16], negatively regulates several target gene expressions, such as those of cyclin G1, serum response factor (Srf), and insulin-like growth factor 1 receptor (Igf1r). This evidence concerns the gene SRF and hepatocellular carcinoma.